ストックスクリーナーアプリを入手
0.5158
3.32%
-0.0177
アフターアワーズ：
.52
0.0042
+0.81%
前日終値:
$0.5335
開ける：
$0.5289
24時間の取引高:
745.41K
Relative Volume:
0.21
時価総額：
$22.93M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.77%
1か月 パフォーマンス:
+8.48%
6か月 パフォーマンス:
-33.53%
1年 パフォーマンス:
-39.25%
1日の値動き範囲:
$0.5009
$0.5595
1週間の範囲:
$0.4831
$0.5899
52週間の値動き範囲:
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.5158 | 22.93M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkgen Biotech Inc (NKGN) 最新ニュース
Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
NKGen Biotech announces administration of first dose of troculeucel - TipRanks
NKGen Biotech Announces Administration of First Dose of - GlobeNewswire
Can NK Cell Therapy Help Stroke Patients? NKGen's FDA-Cleared Treatment Begins Testing - StockTitan
NKGen Biotech Doses First FTD Patient With Troculeucel Under FDA Compassionate Use - Nasdaq
NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com
Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia PatientWill NK Cells Change Neurology? - StockTitan
NKGen Biotech Inc (NKGN) At $0.48: It’s Worth Your Interest - Stocks Register
NKGen Appoints Dr. Anita Fletcher as National Principal - GlobeNewswire
NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer'S Disease With Adventhealth Orlando As First East Coast Site - Marketscreener.com
Can This NK Cell Therapy Transform Alzheimer's Treatment? Phase 1 Shows Remarkable 90% Success - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Midday Stock Roundup: RxSight Down 6.1% on Weak Post-3Q Results - Orange County Business Journal
FDA fast tracks NKGen's Alzheimer's therapy troculeucel - MSN
NKGen Biotech Announces Publication of Phase 1 Troculeucel - GlobeNewswire
Market cap of NKGen Biotech Inc [NKGN] reaches 37.83M – now what? - The DBT News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
NKGen's Troculeucel Therapy Demonstrates Stability And Cognitive Improvement In AD Trial - Nasdaq
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the ... - The Bakersfield Californian
Revolutionary Alzheimer's Treatment Shows Remarkable 90% Success in Phase 1 Trial - StockTitan
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket - Benzinga India
FDA Fast Track Designation Sends Biotech Soaring Mid-Week - The Globe and Mail
FDA fast tracks NKGen's Alzheimer's therapy troculeucel By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug - TradingView
NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate - Marketscreener.com
NKGen Biotech Receives U.S. FDA Fast Track Designation for - GlobeNewswire
Revolutionary NK Cell Therapy for Alzheimer's Disease Receives FDA Fast-Track Status - StockTitan
How to Use the Immune System Against Cancer and Alzheimer's, with Dr. Paul Song - upworthyscience.com
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech selected as preferred stalking horse bidder for NKMax - Nasdaq
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
Nkgen Biotech Inc (NKGN) 財務データ
Nkgen Biotech Inc (NKGN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):